POSTNEOADJUVANT THERAPY STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental virus joins Chemo-Radiation to fight esophageal cancer
Disease control OngoingThis early-phase trial tests whether adding a cancer-killing virus (OBP-301) to standard chemotherapy and radiation is safe for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The study includes 16 participants and focuses on side effects. The …
Matched conditions: POSTNEOADJUVANT THERAPY STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC